{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:44:33Z","timestamp":1788327873156,"version":"build-2803163510"},"reference-count":114,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Chemotherapy-induced alopecia (CIA) is one of the most common and visible toxicities of breast cancer treatment, yet its true incidence, severity, and long-term outcomes remain inconsistently reported. Although CIA is frequently cited as affecting approximately 65% of patients and persistent alopecia has historically been considered uncommon (1\u201315%), emerging data suggest a substantially greater burden. We conducted a scoping review of PubMed, EMBASE, SCOPUS, and Cochrane databases to synthesize regimen-specific evidence on the incidence, severity, and persistence of CIA in breast cancer patients. Anthracycline- and taxane-based regimens were associated with the highest risk, with severe alopecia reported in more than 70% of patients and rates approaching 90\u2013100% in combination regimens. Cyclophosphamide further amplified acute CIA when combined with doxorubicin, with reported incidence up to 93%. In contrast, capecitabine and vinorelbine were consistently associated with lower alopecia incidence. Importantly, CIA was not uniformly reversible. Persistent CIA (pCIA) occurred in up to 67% of patients treated with doxorubicin-based regimens and nearly 50% of those receiving docetaxel combinations, substantially higher than historically reported. Despite its high frequency and potential permanence, CIA remains underreported in oncology trials and insufficiently addressed in survivorship care. Recognizing CIA as both an acute toxicity and a potential long-term survivorship concern underscores the need for standardized reporting, longitudinal follow-up, and development of effective preventive strategies in breast cancer care.<\/jats:p>","DOI":"10.3390\/cancers18050861","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T15:49:42Z","timestamp":1773071382000},"page":"861","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Chemotherapy-Induced Alopecia in Breast Cancer Patients: Treatment-Specific Incidence and Risk of Persistent Hair Loss"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5173-0698","authenticated-orcid":false,"given":"Simonetta I.","family":"Gaumond","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL 33136, USA"},{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Shrestha","sequence":"additional","affiliation":[{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Kamholtz","sequence":"additional","affiliation":[{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela E.","family":"Beraja","sequence":"additional","affiliation":[{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin J.","family":"Jimenez","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL 33136, USA"},{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.pmbts.2017.07.002","article-title":"Breast Cancer Epidemiology, Prevention, and Screening","volume":"151","author":"Winters","year":"2017","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_2","unstructured":"American Cancer Society (2025, February 25). Breast Cancer Statistics|How Common Is Breast Cancer?. Available online: https:\/\/www.cancer.org\/cancer\/types\/breast-cancer\/about\/how-common-is-breast-cancer.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: Global statistics for 2020 and 2040","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.cpet.2018.02.006","article-title":"Overview of Breast Cancer Therapy","volume":"13","author":"Moo","year":"2018","journal-title":"PET Clin."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"102375","DOI":"10.1016\/j.ctrv.2022.102375","article-title":"Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality","volume":"105","author":"Kerr","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"9S","DOI":"10.2967\/jnumed.115.157834","article-title":"Clinical Diagnosis and Management of Breast Cancer","volume":"57","author":"McDonald","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1634\/theoncologist.2018-0184","article-title":"Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study","volume":"24","author":"Kang","year":"2019","journal-title":"Oncologist"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/jocd.12308","article-title":"Chemotherapy-induced alopecia management: Clinical experience and practical advice","volume":"16","author":"Rossi","year":"2017","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.3390\/curroncol30040275","article-title":"Prevention and Treatment of Chemotherapy-Induced Alopecia: What Is Available and What Is Coming?","volume":"30","author":"Wikramanayake","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1055\/s-0041-1741037","article-title":"Psychology of Hair Loss Patients and Importance of Counseling","volume":"54","author":"Dhami","year":"2021","journal-title":"Indian. J. Plast. Surg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/pon.1245","article-title":"Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: A literature review","volume":"17","author":"Lemieux","year":"2008","journal-title":"Psycho-Oncology"},{"key":"ref_13","first-page":"13","article-title":"Permanent alopecia in women being treated for breast cancer","volume":"13","author":"Masidonski","year":"2009","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/DAD.0b013e3181fcfc25","article-title":"Permanent alopecia after systemic chemotherapy: A clinicopathological study of 10 cases","volume":"33","author":"Miteva","year":"2011","journal-title":"Am. J. Dermatopathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10549-018-4855-2","article-title":"Persistent major alopecia following adjuvant docetaxel for breast cancer: Incidence, characteristics, and prevention with scalp cooling","volume":"171","author":"Pinilla","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jaad.2012.02.010","article-title":"Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0","volume":"67","author":"Chen","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1158\/1535-7163.MCT-13-0791","article-title":"Targeting microtubules by natural agents for cancer therapy","volume":"13","author":"Mukhtar","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_18","first-page":"965","article-title":"IFN-gamma enhances paclitaxel-induced apoptosis that is modulated by activation of caspases 8 and 3 with a concomitant down regulation of the AKT survival pathway in cultured human keratinocytes","volume":"13","author":"Hokeness","year":"2005","journal-title":"Oncol. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Quesada, S., Guichard, A., and Fiteni, F. (2021). Cancer-Related Alopecia: From Etiologies to Global Management. Cancers, 13.","DOI":"10.3390\/cancers13215556"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.3390\/curroncol31090423","article-title":"Chemotherapy-Induced Alopecia by Docetaxel: Prevalence, Treatment and Prevention","volume":"31","author":"Perez","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/jnci\/87.15.1169","article-title":"Paclitaxel in metastatic breast cancer: A trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines","volume":"87","author":"Gianni","year":"1995","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1200\/JCO.21.02953","article-title":"Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer","volume":"41","author":"Rugo","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/jamaoncol.2023.2150","article-title":"Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical Trial","volume":"9","author":"Munzone","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1023\/A:1012557528952","article-title":"Weekly docetaxel (Taxotere) in patients with metastatic breast cancer","volume":"12","author":"Stemmler","year":"2001","journal-title":"Ann. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1158\/1078-0432.CCR-14-3252","article-title":"Eribulin Mesylate: Mechanism of Action of a Unique Microtubule Targeting Agent","volume":"21","author":"Risinger","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1021\/bi901810u","article-title":"Eribulin Binds at Microtubule Ends to a Single Site on Tubulin to Suppress Dynamic Instability","volume":"49","author":"Smith","year":"2010","journal-title":"Biochemistry"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1080\/15384101.2020.1716144","article-title":"The microtubule targeting agents eribulin and paclitaxel activate similar signaling pathways and induce cell death predominantly in a caspase-independent manner","volume":"19","author":"Reese","year":"2020","journal-title":"Cell Cycle"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1200\/JCO.2009.25.8467","article-title":"Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1200\/JCO.2008.17.7618","article-title":"Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"27","author":"Vahdat","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","article-title":"Doxorubicin pathways: Pharmacodynamics and adverse effects","volume":"21","author":"Thorn","year":"2011","journal-title":"Pharm. Genom."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Kciuk, M., Gieleci\u0144ska, A., Mujwar, S., Ko\u0142at, D., Ka\u0142uzi\u0144ska-Ko\u0142at, \u017b., Celik, I., and Kontek, R. (2023). Doxorubicin-An Agent with Multiple Mechanisms of Anticancer Activity. Cells, 12.","DOI":"10.3390\/cells12040659"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1634\/theoncologist.2017-0263","article-title":"A Clinical and Biological Guide for Understanding Chemotherapy-Induced Alopecia and Its Prevention","volume":"23","author":"Dunnill","year":"2018","journal-title":"Oncologist"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/sj.jid.5700486","article-title":"Chemotherapy targets the hair-follicle vascular network but not the stem cells","volume":"127","author":"Amoh","year":"2007","journal-title":"J. Investig. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.jid.5700175","article-title":"Doxorubicin-induced alopecia is associated with sebaceous gland degeneration","volume":"126","author":"Selleri","year":"2006","journal-title":"J. Investig. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/ijd.15812","article-title":"Post-chemotherapy alopecia: What the dermatologist needs to know","volume":"60","author":"Santos","year":"2021","journal-title":"Int. J. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"Wigler","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1200\/JCO.1985.3.6.818","article-title":"A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer","volume":"3","author":"Jain","year":"1985","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1200\/JCO.1989.7.5.560","article-title":"Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer","volume":"7","author":"Henderson","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0936-6555(96)80079-3","article-title":"Comparison of mitozantrone and epirubicin in advanced breast cancer","volume":"8","author":"Cook","year":"1996","journal-title":"Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1023\/A:1006394801389","article-title":"Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients","volume":"59","author":"Michelotti","year":"2000","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1007\/s11010-023-04805-0","article-title":"Molecular mechanisms underlying cyclophosphamide-induced cognitive impairment and strategies for neuroprotection in preclinical models","volume":"479","author":"Ibrahim","year":"2024","journal-title":"Mol. Cell. Biochem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF01806239","article-title":"Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer","volume":"3","author":"Brincker","year":"1983","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: Mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1634\/theoncologist.2011-0281","article-title":"Capecitabine monotherapy: Review of studies in first-line HER-2-negative metastatic breast cancer","volume":"17","author":"Kaufmann","year":"2012","journal-title":"Oncologist"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1016\/j.ejca.2010.07.009","article-title":"First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: Results of the MONICA trial","volume":"46","author":"Kaufmann","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4498","DOI":"10.1200\/JCO.2010.33.9101","article-title":"Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer","volume":"29","author":"Stockler","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000111094","article-title":"An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer","volume":"72","author":"Venturini","year":"2007","journal-title":"Oncology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ctrv.2005.12.008","article-title":"Vinorelbine in the management of breast cancer: New perspectives, revived role in the era of targeted therapy","volume":"32","author":"Mano","year":"2006","journal-title":"Cancer Treat. Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/tbj.12071","article-title":"A systematic review of vinorelbine for the treatment of breast cancer","volume":"19","author":"Xu","year":"2013","journal-title":"Breast J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/oxfordjournals.annonc.a058873","article-title":"Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer","volume":"5","author":"Degardin","year":"1994","journal-title":"Ann. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1023\/A:1008364222793","article-title":"Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older","volume":"10","author":"Vogel","year":"1999","journal-title":"Ann. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.clbc.2017.05.012","article-title":"Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study","volume":"18","author":"Steger","year":"2018","journal-title":"Clin. Breast Cancer"},{"key":"ref_54","first-page":"24","article-title":"A phase II study of doxorubicin\/paclitaxel plus G-CSF for metastatic breast cancer","volume":"11","author":"Schwartsmann","year":"1997","journal-title":"Oncology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00432-004-0599-y","article-title":"Primary chemotherapy with doxorubicin and paclitaxel in patients with early breast cancer: Final results of a multicenter phase II study","volume":"130","author":"Schmid","year":"2004","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Yang, H., Xu, L., Guan, S., Hao, X., Ge, Z., Tong, F., Cao, Y., Liu, P., Zhou, B., and Cheng, L. (2022). Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: An open-label, randomized, multi-center, phase II Trial. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-10439-0"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S1470-2045(22)00632-5","article-title":"Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): End-of-study results from a randomised, phase 3 trial","volume":"23","author":"Poggio","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/annonc\/mdq392","article-title":"Weekly combination of non-pegylated liposomal doxorubicin and taxane in first-line breast cancer: wALT trial (phase I\u2013II)","volume":"22","author":"Rosati","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Allouache, D., Gawande, S.R., Tubiana-Hulin, M., Tubiana-Mathieu, N., Piperno-Neumann, S., Mefti, F., Bozec, L., and Genot, J.-Y. (2005). First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: A phase II study. BMC Cancer, 5.","DOI":"10.1186\/1471-2407-5-151"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1470-2045(15)70064-1","article-title":"Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): A randomised, open-label, multicentre, phase 3 trial","volume":"16","author":"Hu","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/jjco\/hyq232","article-title":"Weekly paclitaxel combining with gemcitabine is an effective and safe treatment for advanced breast cancer patients","volume":"41","author":"Rau","year":"2011","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/annonc\/mdx505","article-title":"Veliparib with temozolomide or carboplatin\/paclitaxel versus placebo with carboplatin\/paclitaxel in patients with BRCA1\/2 locally recurrent\/metastatic breast cancer: Randomized phase II study","volume":"29","author":"Han","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1002\/cncr.30170","article-title":"Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study","volume":"122","author":"Ferrero","year":"2016","journal-title":"Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.clbc.2019.02.008","article-title":"Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE)","volume":"19","author":"Woodward","year":"2019","journal-title":"Clin. Breast Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/tbj.12098","article-title":"A three-arm randomized phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines","volume":"19","author":"Campone","year":"2013","journal-title":"Breast J."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Liu, D., Wu, J., Lin, C., Ding, S., Lu, S., Fang, Y., Huang, J., Hong, J., Gao, W., and Zhu, S. (2022). The Comparative Safety of Epirubicin and Cyclophosphamide versus Docetaxel and Cyclophosphamide in Lymph Node-Negative, HR-Positive, HER2-Negative Breast Cancer (ELEGANT): A Randomized Trial. Cancers, 14.","DOI":"10.3390\/cancers14133221"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1159\/000086986","article-title":"Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: Results of a multicenter phase II study","volume":"68","author":"Palmeri","year":"2005","journal-title":"Oncology"},{"key":"ref_68","first-page":"1051","article-title":"Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor","volume":"8","author":"Kornek","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1053\/j.seminoncol.2004.03.025","article-title":"Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy in stage II and III breast cancer patients: Preliminary results of a phase II and pharmacogenomic study","volume":"31","author":"Calvo","year":"2004","journal-title":"Semin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1200\/JCO.2001.19.3.621","article-title":"Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor","volume":"19","author":"Kornek","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10549-021-06145-3","article-title":"Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study","volume":"187","author":"Kuemmel","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10549-023-07073-0","article-title":"A phase Ib\/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer","volume":"203","author":"Gumusay","year":"2024","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"100019","DOI":"10.1016\/j.esmoop.2020.100019","article-title":"Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)","volume":"6","author":"Pellegrino","year":"2020","journal-title":"ESMO Open"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13058-025-02108-4","article-title":"Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: A phase II study","volume":"27","author":"Fanucci","year":"2025","journal-title":"Breast Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"100054","DOI":"10.1016\/j.esmoop.2021.100054","article-title":"Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: A multicenter, phase II, single arm trial (GIM11-BERGI)","volume":"6","author":"Bruzzese","year":"2021","journal-title":"ESMO Open"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"113386","DOI":"10.1016\/j.ejca.2023.113386","article-title":"Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB\/II study (KCSG BR18-16)","volume":"195","author":"Kim","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-20-4726","article-title":"Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib\/II Study","volume":"27","author":"Tolaney","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1200\/JCO.1990.8.9.1483","article-title":"Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15","volume":"8","author":"Fisher","year":"1990","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"812","DOI":"10.4143\/crt.2018.383","article-title":"A Phase II Study to Evaluate the Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients Receiving Dose-Dense Doxorubicin\/Cyclophosphamide","volume":"51","author":"Kim","year":"2019","journal-title":"Cancer Res. Treat."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"103725","DOI":"10.1016\/j.breast.2024.103725","article-title":"Phase II randomized trial comparing metronomic anthracycline-containing chemotherapy versus standard schedule in untreated HER2 negative advanced breast cancer: Activity and quality of life results of the GOIM 21003 trial","volume":"75","author":"Orlando","year":"2024","journal-title":"Breast"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF00174167","article-title":"A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer","volume":"3","author":"Bennett","year":"1985","journal-title":"Investig. New Drugs"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/annonc\/mdg260","article-title":"Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: A study by the GEICAM group","volume":"14","author":"Martin","year":"2003","journal-title":"Ann. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1038\/bjc.1996.668","article-title":"Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer","volume":"74","author":"Gabra","year":"1996","journal-title":"Br. J. Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1023\/A:1006121608414","article-title":"Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: Results of a phase I study","volume":"16","author":"Flath","year":"1998","journal-title":"Investig. New Drugs"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/01.coc.0000128527.95562.ae","article-title":"Gemcitabine combined with epirubicin in the treatment of patients with locally advanced or metastatic breast cancer: A phase II study","volume":"27","author":"Hausmaninger","year":"2004","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3109\/02841869209088908","article-title":"FEC (5-fluorouracil-epirubicin-cyclophosphamide) monthly versus FEC weekly in metastatic breast cancer. First results of a randomized trial","volume":"31","author":"Blomqvist","year":"1992","journal-title":"Acta Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/00000421-200108000-00018","article-title":"Combined 5-fluorouracil infusion with fractionated epirubicin and cyclophosphamide in advanced breast cancer","volume":"24","author":"Recchia","year":"2001","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3816\/CBC.2006.n.005","article-title":"Capecitabine\/vinorelbine: An effective and well-tolerated regimen for women with pretreated advanced-stage breast cancer","volume":"6","author":"Catania","year":"2006","journal-title":"Clin. Breast Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s10549-025-07873-6","article-title":"Antitumor activity of the combination of vinorelbine and gemcitabine in patients with HR\u2009+\u2009\/HER2- advanced breast cancer after CDK4\/6 inhibitor","volume":"215","author":"Jara","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1023\/A:1008334227668","article-title":"Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: A phase II study","volume":"12","author":"Munzone","year":"2001","journal-title":"Ann. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1023\/A:1008209429204","article-title":"Phase I\u2013II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: A regimen with a low subjective toxic burden","volume":"8","author":"Aapro","year":"1997","journal-title":"Ann. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3816\/CBC.2008.n.019","article-title":"Phase II trial of gemcitabine\/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer","volume":"8","author":"Loesch","year":"2008","journal-title":"Clin. Breast Cancer"},{"key":"ref_93","first-page":"e13395","article-title":"Permanent hair loss associated with taxane chemotherapy use in breast cancer: A retrospective survey at two tertiary UK cancer centres","volume":"30","author":"Chan","year":"2021","journal-title":"Eur. J. Cancer Care"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1200\/JCO.23.02374","article-title":"Scalp Cooling in Preventing Persistent Chemotherapy-Induced Alopecia: A Randomized Controlled Trial","volume":"42","author":"Kang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/annonc\/mds095","article-title":"Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil\/epirubicin\/cyclophosphamide (FEC) and docetaxel: A prospective study of 20 patients","volume":"23","author":"Kluger","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1200\/JCO.2015.61.9510","article-title":"Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM\/2003-10 Study","volume":"33","author":"Ribelles","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamadermatol.2021.3676","article-title":"Clinicopathologic Characteristics and Response to Treatment of Persistent Chemotherapy-Induced Alopecia in Breast Cancer Survivors","volume":"157","author":"Bhoyrul","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1023\/A:1005882314735","article-title":"Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer","volume":"45","author":"Murad","year":"1997","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1016\/S1470-2045(12)70553-3","article-title":"Pathobiology of chemotherapy-induced hair loss","volume":"14","author":"Paus","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"tkac022","DOI":"10.1093\/burnst\/tkac022","article-title":"Regulation of signaling pathways in hair follicle stem cells","volume":"10","author":"Wang","year":"2022","journal-title":"Burn. Trauma"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12929-020-0624-8","article-title":"Functional complexity of hair follicle stem cell niche and therapeutic targeting of niche dysfunction for hair regeneration","volume":"27","author":"Chen","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/bph.12068","article-title":"Enhanced anti-tumour effects of Vinca alkaloids given separately from cytostatic therapies","volume":"168","author":"Ehrhardt","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"6123","DOI":"10.1182\/blood-2010-02-269811","article-title":"Optimized anti\u2013tumor effects of anthracyclines plus Vinca alkaloids using a novel, mechanism-based application schedule","volume":"118","author":"Ehrhardt","year":"2011","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: The \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Sig. Transduct. Target. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"102113","DOI":"10.1016\/j.eclinm.2023.102113","article-title":"Toxicity profile of antibody-drug conjugates in breast cancer: Practical considerations","volume":"62","author":"Verrazzo","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s11864-025-01336-2","article-title":"Cancer-Related Alopecia Risk and Treatment","volume":"26","author":"Kaufman","year":"2025","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2009.23.8162","article-title":"Male breast cancer: A population-based comparison with female breast cancer","volume":"28","author":"Anderson","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_110","first-page":"543","article-title":"Chemotherapy-induced alopecia: Psychosocial impact and therapeutic approaches","volume":"12","author":"Hesketh","year":"2004","journal-title":"Support. Care Cancer"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1523-5394.2001.96007.x","article-title":"Psychological sequelae and alopecia among women with cancer","volume":"9","author":"McGarvey","year":"2001","journal-title":"Cancer Pract."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.7314\/APJCP.2015.16.3.1225","article-title":"Psychosocial reaction patterns to alopecia in female patients with gynecological cancer undergoing chemotherapy","volume":"16","author":"Ishida","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jama.2016.20939","article-title":"Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial","volume":"317","author":"Nangia","year":"2017","journal-title":"JAMA"},{"key":"ref_114","first-page":"6641","article-title":"Comparable effectiveness of 45- and 20-min post-infusion scalp cooling time in preventing paclitaxel-induced alopecia\u2014A randomized controlled trial","volume":"30","author":"Lugtenberg","year":"2022","journal-title":"Support. Care Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/5\/861\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T16:02:11Z","timestamp":1773072131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/5\/861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":114,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["cancers18050861"],"URL":"https:\/\/doi.org\/10.3390\/cancers18050861","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]}}}